Claims
- 1. A compound having the formula (I):
- 2. The compound of claim 1, wherein R4 is hydrogen.
- 3. The compound of claim 1, wherein R″ is hydrogen.
- 4. The compound of claim 3, wherein R2 is (C1-C4)alkyl or aryl.
- 5. The compound of claim 4, wherein R1 is independently selected from the group consisting of halogen, (C1-C4)alkyl, fluoro(C1-C4)alkyl, —OR5, fluoro(C1-C4)alkoxy, —CO2R5, —S(O)mNR5R6, S(O)mR5 and —CN.
- 6. The compound of claim 5, wherein R1 is halogen or fluoro(C1-C4)alkyl.
- 7. The compound of claim 5, wherein n is 0 or 1.
- 8. The compound of claim 7, wherein L is (C1-C4)alkylene.
- 9. The compound of claim 8, having the formula (III):
- 10. The compound of claim 8, wherein p is 1, 2 or 3.
- 11. The compound of claim 10, wherein R and R′ are combined to form a 3-, 4-, 5-, 6- or 7-membered ring containing nitrogen and from 0 to 2 additional heteroatoms selected from the group consisting of O, N and S.
- 12. A compound having the formula (II):
- 13. The compound of claim 12, wherein R4 is hydrogen.
- 14. The compound of claim 13, wherein R″ is hydrogen.
- 15. The compound of claim 14, wherein R2 is (C1-C4)alkyl or aryl.
- 16. The compound of claim 15, wherein R1 is independently selected from the group consisting of halogen, (C1-C4)alkyl, fluoro(C1-C4)alkyl, —OR5, fluoro(C1-C4)alkoxy, —CO2R5, —S(O)mNR5R6, —S(O)mR5 and —CN.
- 17. The compound of claim 16, wherein R1 is halogen or fluoro(C1-C4)alkyl.
- 18. The compound of claim 16, wherein R1 is fluoro(C1-C4)alkyl.
- 19. The compound of claim 16, wherein n is 0 or 1.
- 20. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound of any one of claims 1-19.
- 21. A method for treating a condition or disorder is selected from the group consisting of obesity, an eating disorder, an anxiety disorder and a mood disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.
- 22. The method of claim 21, wherein said compound condition or disorder is selected from the group consisting of obesity, anorexia nervosa, anxiety, panic disorder and obsessive-compulsive disorder and depression.
- 23. The method of claim 21, wherein said compound is administered in combination with an anti-obesity agent, an antidepressant or an anxiolytic agent.
- 24. The method of claim 21, wherein said compound is administered orally.
- 25. The method of claim 21, wherein said compound is administered parenterally.
- 26. The method of claim 21, wherein said compound modulates MCHR.
- 27. A method for modifying eating behavior, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.
- 28. The method of claim 27, wherein food intake is decreased.
- 29. The method of claim 27, wherein food intake is increased.
- 30. A method for treating a condition or disorder mediated by MCHR, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.
- 31. The method of claim 30, wherein said condition or disorder is selected from the group consisting of obesity, an eating disorder, an anxiety disorder and a mood disorder.
- 32. The method of claim 31, wherein said eating disorder is anorexia nervosa.
- 33. The method of claim 31, wherein said anxiety disorder is selected from the group consisting of anxiety, panic disorder and obsessive-compulsive disorder.
- 34. The method of claim 31, wherein said mood disorder is depression.
- 35. A method for modulating MCHR, comprising contacting a cell with a compound of claim 1.
- 36. The method of claim 35, wherein said compound is an MCHR antagonist.
- 37. The method of claim 35, wherein said compound is an MCHR agonist.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is related to U.S. patent application Ser. No. 10/138,279, filed May 3, 2002, and International Application No. PCT/US02/13856, filed May 3, 2002, which claim the benefit of U.S. Application Serial No. 60/288,665, filed May 4, 2001, the disclosures of which are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60288665 |
May 2001 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
10138279 |
May 2002 |
US |
Child |
10289933 |
Nov 2002 |
US |